医学
比例危险模型
脑积水
生存分析
立体定向活检
开颅术
胶质瘤
性能状态
回顾性队列研究
少突胶质瘤
外科
内科学
少突胶质瘤
肿瘤科
星形细胞瘤
活检
癌症
癌症研究
作者
Yoshua Esquenazi,Nelson Moussazadeh,Thomas W. Link,Koos E. Hovinga,Anne S. Reiner,Natalie M. DiStefano,Cameron Brennan,Philip H. Gutin,Viviane Tabar
出处
期刊:Neurosurgery
[Lippincott Williams & Wilkins]
日期:2017-05-24
卷期号:83 (1): 76-85
被引量:44
标识
DOI:10.1093/neuros/nyx349
摘要
Abstract BACKGROUND Thalamic glioblastomas (GBMs) represent a significant neurosurgical challenge. In view of the low incidence of these tumors, outcome data and management strategies are not well defined. OBJECTIVE To identify the natural history and factors associated with survival in patients with thalamic glioblastoma. METHODS A retrospective review of all patients with thalamic glioblastoma over a 10-yr period was performed. Presenting clinical, radiological, and outcome data were collected. Chi-squared and Fisher's exact tests were used to compare clinical characteristics across tumor groups. Cox proportional hazard models were utilized to investigate variables of interest with regard to overall survival. RESULTS Fifty-seven patients met inclusion criteria, with a median age of 53 and median Karnofsky Performance Scale (KPS) score of 80. The most common presenting symptoms were weakness, confusion, and headache. Hydrocephalus was present in 47% of patients preoperatively. Stereotactic biopsy was performed in 47 cases, and 10 patients underwent craniotomy. The median overall survival was 12.2 mo. Higher KPS, younger age, and cerebrospinal fluid (CSF) diversion were correlated with better overall survival univariately, respectively, while the presence of language deficits at initial presentation was associated with poorer survival. In multivariate analysis, the only significant predictor of survival was presenting KPS. CONCLUSION The overall survival of patients with thalamic glioblastoma is comparable to unresectable lobar supratentorial GBMs. Younger patients and those with good presenting functional status had improved survival. Midbrain involvement by the tumor is not a negative prognostic factor. Improved therapies are needed, and patients should be considered for early trial involvement and aggressive upfront therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI